Biosignatures is Decision/Risk Analysis in United Kingdom that focus on subsequent diagnosis business. Founded in 2007. They cover business area such as developer, molecular diagnostic test, disease biomarker, blood, early detection, subsequent diagnosis, life-threaten disease, multiple protein base disease diagnostic, multiple proteoform monitoring, urological cancer, doctor, healthcare, non-invasive method.
2007
( 17 years old in 2024 )
Subsequent Diagnosis
-
Fourth Floor, Dean Court
22 Dean Street
Newcastle upon Tyne NE1 1PG
England, United Kingdom
Private
developermolecular diagnostic testdisease biomarkerbloodearly detectionsubsequent diagnosislife-threaten diseasemultiple protein base disease diagnosticmultiple proteoform monitoringurological cancerdoctorhealthcarenon-invasive method
* We use standard office opening hours in near Biosignatures's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Biosignatures is Decision/Risk Analysis business from United Kingdom that founded in 2007 (17 years old in 2024), Biosignatures business is focusing on Subsequent Diagnosis.
Biosignatures headquarter office and corporate office address is located in Fourth Floor, Dean Court 22 Dean Street Newcastle upon Tyne NE1 1PG England, United Kingdom.
Biosignatures was founded in United Kingdom.
In 2024, Biosignatures is currently focus on subsequent diagnosis sector.
Above is snippet of Google Trends for "subsequent diagnosis" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Biosignatures, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
